Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold

Bellamy, Valérie; Vanneaux, Valérie; Bel, Alain; Nemetalla, Hany; Boitard, Solène Emmanuelle; Farouz, Yohan; Joanne, Pierre; Perier, Marie‐Cécile; Robidel, Estelle; Mandet, Chantal; Hagège, Albert; Bruneval, Patrick; Larghero, Jérôme; Agbulut, Onnik; Menasché, Philippe

doi:10.1016/j.healun.2014.10.008

Cited by 85 publications

(56 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One current clinical trial is actively recruiting patients to test the use of human ESC-derived cardiac progenitor cells in patients with heart failure (NCT02057900) (119). On the basis of their preclinical data showing a significant improvement in cardiac function due to paracrine effects of the transplanted cardiac progenitor cells (120), this ongoing clinical trial is using fibrin patches containing Isl-1 + SSEA-1 + cells. The trial's first clinical case report has found improvement in patient's functional outcomes and evidence of new-onset contractility of the transplanted area (121).…”

Section: Applications Of Ipscsmentioning

confidence: 99%

Translation of Human-Induced Pluripotent Stem Cells

Sayed

2016

Journal of the American College of Cardiology

234

View full text Add to dashboard Cite

The prospect of changing the plasticity of terminally differentiated cells toward pluripotency has completely altered the outlook of biomedical research. Human induced pluripotent stem cells (iPSCs) provide a new source of therapeutic cells free from the ethical issues or immune barriers of human embryonic stem cells. iPSCs also confer considerable advantages over conventional methods of studying human diseases. Since its advent, iPSC technology has expanded, with 3 major applications: disease modeling; regenerative therapy; and drug discovery. Here we discuss, in a comprehensive manner, the recent advances in iPSC technology in relation to basic, clinical, and population health.

show abstract

Section: Applications Of Ipscsmentioning

confidence: 99%

Translation of Human-Induced Pluripotent Stem Cells

Sayed

2016

Journal of the American College of Cardiology

234

View full text Add to dashboard Cite

show abstract

“…Also related to gestation, MSCs obtained from fetal heart tissue (fC-MSC) and embryonic stem cells (ESC) have been proposed as alternative multipotent cells with the ability to differentiate into CMs, endothelial and smooth muscle cells. However, the use of such cells is obviated by evident ethical dilemmas [52][53][54][55].…”

Section: Stem Cells Obtained From Pregnancy Byproducts and Other Gestmentioning

confidence: 99%

“…Also, they promote migration of endothelial cells and smooth muscle cells and, simultaneously, confer CMs protection from apoptosis. In addition, these materials have low immunogenicity and have anti-inflammatory and pro-angiogenic properties [17,18,20,37,50,53,67,107,108,112,115]. This explains why delivery of stem cells in scaffolds has higher benefits to those delivered in aqueous or in culture media, with regard to cell retention and proliferation as well as structural and functional myocardial recovery.…”

Section: Combination Of Different Stem Cellsmentioning

confidence: 99%

“…[15,30,34,76,102]), intravenous (IVI, [44,54]) and intramuscular injections [46] and epicardial delivery (e.g. [17,53,[64][65][66]) are routes of choice, too. Stem cells can be administered directly by IMI or by epicardial delivery, although one should realize that these are very invasive procedures that can compromise the condition of the patients even further.…”

Section: Clinical Translationmentioning

confidence: 99%

See 1 more Smart Citation

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Trindade

Leite‐Moreira

Ferreira-Martins

et al. 2017

International Journal of Cardiology

View full text Add to dashboard Cite

Today there is an increasing demand for heart transplantations for patients diagnosed with heart failure. Though, shortage of donors as well as the large number of ineligible patients hurdle such treatment option. This, in addition to the considerable number of transplant rejections, has driven the clinical research towards the field of regenerative medicine. Nonetheless, to date, several stem cell therapies tested in animal models fall by the wayside and when they meet the criteria to clinical trials, subjects often exhibit modest improvements. A main issue slowing down the admission of such therapies in the domain of human trials is the lack of protocol standardization between research groups, which hampers comparison between different approaches as well as the lack of thought regarding the clinical translation. In this sense, given the large amount of reports on stem cell therapy studies in animal models reported in the last 3 years, we sought to evaluate their advantages and limitations towards the clinical setting and provide some suggestions for the forthcoming investigations. We expect, with this review, to start a new paradigm on regenerative medicine, by evoking the debate on how to plan novel stem cell therapy studies with animal models in order to achieve more consistent scientific production and accelerate the admission of stem cell therapies in the clinical setting.

show abstract

“…Plusieurs équipes expérimentent l'application sur les zones pathologiques cibles des feuilles de cellules, ou de matrices cellularisées biodégradables à base d'alginates, de Matrigel, de fibrine, de polysaccharides, de gélatine, de collagène, dans différentes espèces animales (Souris, Rat, Cochon d'Inde, Mouton, Macaque) [29]. Certaines matrices favorisent la survie cellulaire et promeuvent l'angiogénèse locale, et dans des modèles post-ischémiques, ces greffons améliorent la fonction cardiaque [30,31]. Des progrès restent à accomplir concernant l'intégration réelle de ces biomatériaux, leur vascularisation, leur colonisation par des cellules de l'hôte, et réci-proquement la migration des cellules qu'elles contiennent vers le tissu cardiaque hôte.…”

Section: Délivrance Des Cellules Biomatériaux Et Suivi Des Cellulesunclassified

Thérapies cellulaires des cardiopathies

Vilquin¹,

Etienne²

2016

Med Sci (Paris)

View full text Add to dashboard Cite

L’insuffisance cardiaque est un problème majeur de santé publique et différentes approches de thérapie cellulaire sont expérimentées pour améliorer la fonction de myocardes défaillants. De nombreux types cellulaires ont été utilisés (myoblastes squelettiques, cellules hématopoïétiques, endothéliales ou mésenchymateuses, cellules d’origine cardiaque…), plus souvent dans des indications d’insuffisance post-ischémique que de cardiomyopathie dilatée génétique. Il est en effet plus aisé de cibler une zone de réparation localisée que l’ensemble du tissu myocardique. De nombreux essais cliniques ont fait état de résultats fonctionnels de faibles ampleurs mais encourageants, dont l’interprétation est souvent limitée par la taille des cohortes et les variabilités biologiques liées aux patients et aux candidats cellulaires. Ces essais ont aussi mis en lumière des mécanismes d’action inattendus, qui changent les concepts et méthodologies de traitement. En effet, les bénéfices proviendraient de sécrétions de facteurs trophiques, plutôt que d’une intégration structurale des cellules au sein du myocarde. Par conséquent, les nouvelles générations d’essais visent à accroître la taille et l’homogénéité des cohortes de patients afin d’améliorer la puissance statistique. Par ailleurs, des études misent sur l’accompagnement et/ou le conditionnement des cellules à l’aide de biomatériaux et/ou de cocktails de cytokines, en vue d’améliorer leur survie et leur fonctionnement. En parallèle, de nombreuses recherches en bio-ingénierie s’intéressent au soutien des cellules, au maintien de la structure du myocarde, à la fabrication ex vivo de tissu cardiaque de substitution, et finalement à la possibilité de remplacer les cellules par leurs produits actifs de sécrétion. Plusieurs dispositifs devraient émerger de ces recherches, dont le choix sera guidé par l’indication médicale.

show abstract

Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold

Cited by 85 publications

References 47 publications

Translation of Human-Induced Pluripotent Stem Cells

Translation of Human-Induced Pluripotent Stem Cells

Towards the standardization of stem cell therapy studies for ischemic heart diseases: Bridging the gap between animal models and the clinical setting

Thérapies cellulaires des cardiopathies

Contact Info

Product

Resources

About